\n
<\/p>\n
On TV, in magazines and on social media: glucagon-like peptide 1 (GLP-1) agonist drugs such as Mounjaro, Wegovy and, especially, Ozempic are inescapable right now.<\/p>\n
\n
<\/p>\n
In just a few short years, they have profoundly altered the way we view weight management and metabolic wellness, generating billions of dollars in the process.1<\/p>\n
\n
<\/p>\n
But this is only part of the story. The more mainstream GLP-1 agonists become, the more concerns grow surrounding their side-effects, as well as questions about accessibility and long-term efficacy.2,3<\/p>\n
\n
<\/p>\n
So what does this all mean for nutraceutical producers? We\u2019ve already seen significant opportunities emerge for the development of \u201cGLP-1 companion products\u201d to soothe common symptoms and fill nutritional gaps, but could there be another way to tap into this undeniable demand?\u00a0<\/p>\n
Not yet a Subscriber<\/strong>?<\/p>\n \n This is a small extract of the full article which is available ONLY<\/strong> to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.<\/strong><\/p>\n Subscribe now<\/a>
\n Already a subscriber? Sign in here.<\/a><\/p>\n
![\"\"](\"https:\/\/nutraceuticalbusinessreview.com\/banner-image\/3366.png\")
<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
On TV, in magazines and on social media: glucagon-like peptide 1 (GLP-1) agonist drugs such as…\n","protected":false},"author":3,"featured_media":191025,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[210,1182,67,132,68],"class_list":{"0":"post-191024","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nutrition","8":"tag-health","9":"tag-nutrition","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115127860888727718","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/191024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=191024"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/191024\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/191025"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=191024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=191024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=191024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}